title: [Adriamycin thermotherapy through hepatic artery for model of VX2 carcinoma in rabbit liver].
abstract: OBJECTIVE
  It was reported that heating can enhance sensitivity of rabbit VX2 cell to adriamycin and increase intracellular concentration of adriamycin. This study was designed to evaluate the anti-tumor effects of interventional hyperthermia and interventional chemotheramotherapy on VX2 carcinoma in rabbit liver.
  
  
  METHODS
  VX2 carcinoma cells were surgically implanted into the right liver lobe of 60 male New Zealand white rabbits, which were randomly divided into 4 groups(15 rabbits per group). To inject physiological saline(37 degrees C), adriamycin (37 degrees C), physiological saline(60 degrees C), and adriamycin (60 degrees C) in different groups via hepatic artery of the rabbits with liver cancer. One week later, to observe the volume of tumor, the serum level of aspartate transaminase(AST), and observe the survival period of VX2 rabbits.
  
  
  RESULTS
  In group of ADM(60 degrees C), the tumor growth rate (0.53 +/- 0.21)% was significantly lower than group 2(1.09 +/- 0.26)%, group 3(3.32 +/- 1.28)%, and group 4(3.48 +/- 1.17)% (P < 0.05, P < 0.05, P < 0.01, respectively). The survival period of adriamycin (60 degrees C) group (50.0 +/- 2.0)d was significantly higher than the untreated control group (40.5 +/- 3.0)d, (P < 0.05). The serum level of AST of TNP-470 with lipiodol group was not higher than the other treated groups(P > 0.05), but being significantly higher than the untreated control group after treated(P < 0.05).
  
  
  CONCLUSIONS
  Adriamycin (60 degrees C) greatly decreases the tumour growth rate, and prolongs the survival period.
authors.affiliation: Department of Interventional Radiology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, P. R. China. tdjrfsk@fmmu.edu.cn
authors.forename: Hong-xin
authors.initials: HX
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Cao
authors.forename: Zhi-min
authors.initials: ZM
authors.lastname: Wang
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Guo
authors.forename: Dai-hui
authors.initials: DH
authors.lastname: Ni
authors.forename: Yi-yong
authors.initials: YY
authors.lastname: Liu
authors.forename: Yi-qing
authors.initials: YQ
authors.lastname: Wang
authors.forename: Wen-xian
authors.initials: WX
authors.lastname: Li
authors.forename: Ai-lin
authors.initials: AL
authors.lastname: Fan
authors.forename: Rui-yang
authors.initials: RY
authors.lastname: Han
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000627:therapeutic use*; D006499:Hepatic Artery; D006979:Hyperthermia, Induced / Q000379:methods*; D007269:Injections, Intra-Arterial; D008114:Liver Neoplasms, Experimental / Q000473:pathology / Q000628:therapy*; D008297:Male; D009368:Neoplasm Transplantation; D011817:Rabbits; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D001219:Aspartate Aminotransferases